-
NIH Sep 5, 2013 | U19
NSIGHT: Sequencing of Newborn Blood Spot DNA to Improve and Expand Newborn Screening
Institution: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
FOA Number: PA-18-591
Abstract
The purpose of the Newborn Sequencing In Genomic medicine and public HealTh (NSIGHT) program is to explore, in a limited but deliberate manner, the implications, challenges and opportunities associated with the possible use of genomic sequence information in the newborn period. Funds will be used to stimulate research in three component projects specifically applicable to newborn screening:
1) Acquisition and analysis of genomic datasets that expand considerably the scale of data available for analysis in the newborn period.
2) Clinical research that will advance understanding of specific disorders identifiable via newborn screening through promising new DNA-based analysis.
3) Research related to the ethical, legal and social implications (ELSI) of the possible implementation of genomic sequencing of newborns.
FUNDING AGENCY:
Funder:
NIHInstitute:
EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTFunding Type:
U19Project Number:
U19HD077627Start Date:
Sep 5, 2013End Date:
Aug 31, 2018PROJECT TERMS:
base, Biochemical, Biological Assay, Blood, Child, Clinical, Clinical Data, congenital immunodeficiency, Constitutional, cost, cost effective, Data, Disease, DNA, drug metabolism, Ethics, Excision, exome sequencing, falls, Genes, genetic variant, genome analysis, health benefit, Health Policy, Immune System Diseases, improved, Incidental Findings, interest, Laws, Legal, Link, Metabolic, Metabolic Diseases, Methods, Mutation, neonatal period, Neonatal Screening, Newborn Infant, Parents, Participant, Policies, preference, programs, Public Health, Recommendation, Risk, Scanning, Science Policy, screening, Screening procedure, screening program, Sensitivity and Specificity, Severe Combined Immunodeficiency, Spottings, T-Cell Receptor, Technology, Testing, whole genome